Viking Therapeutics has strong R&D, dual-track obesity drugs, and solid cash runway. Click here to read an analysis of VKTX ...

Eli Lilly's Alzheimer's drug, donanemab (Kisqali), just got a thumbs-up from the European Medicines Agency's (EMA) expert ...

Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

We came across a bullish thesis on Eli Lilly and Company on Stock Analysis Compilation’s Substack. In this article, we will ...

Eli Lilly's biggest growth driver, tirzepatide, will continue facing scrutiny from investors and analysts. The company's oral ...

Eli Lilly's stock price shot up by 2.89% on a massive trading volume of 21.27 billion, signaling strong investor interest.

Early intervention in psoriatic arthritis (PsA) is disease-modifying, and delays in diagnosis, even by 6 months, can reduce ...

Alberto Conca, CIO at Swiss wealth manager LFG+ZEST, has been adding exposure to pharma, biotech and medtech in recent weeks, ...

Pharmaceutical giant Eli Lilly delivers strong financial results and has a deep lineup and pipeline. Much smaller Viking Therapeutics boasts several candidates whose progress could jolt its shares.

Few things can jolt a pharmaceutical company's shares like positive results from highly anticipated clinical trials. Even so, ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

On Thursday’s episode of Mad Money, host Jim Cramer turned his focus to large-cap stocks that surged by $10 or more in a single day.